| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/24/2003 | WO2003032982A1 Bis-heteroaryl alkanes as therapeutic agents |
| 04/24/2003 | WO2003032981A1 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes |
| 04/24/2003 | WO2003032980A1 5'-carbamoyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 04/24/2003 | WO2003032979A1 Malignant cell differentiation inducer compositions and utilization of the same |
| 04/24/2003 | WO2003032978A1 Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt |
| 04/24/2003 | WO2003032977A1 Method of treating acne vulgaris using avermectin compound |
| 04/24/2003 | WO2003032976A1 Method of treating dermatoses using avermectin compound |
| 04/24/2003 | WO2003032975A1 Modulation of ocular growth and myopia by gaba drugs |
| 04/24/2003 | WO2003032974A2 Use of sulfonamide derivatives as pharmaceuticals compounds |
| 04/24/2003 | WO2003032973A2 Composition comprising paracetamol and a bitterness masking component |
| 04/24/2003 | WO2003032972A1 5’-carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 04/24/2003 | WO2003032971A1 5’-acylamino-1,1’-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 04/24/2003 | WO2003032970A1 5'-carbamoyl-2'-methyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 04/24/2003 | WO2003032969A2 Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications |
| 04/24/2003 | WO2003032968A1 Compositions for lessening oxidative stress |
| 04/24/2003 | WO2003032967A1 Method of stabilizing reduced coenzyme q10 |
| 04/24/2003 | WO2003032966A1 Compositions for potentiating glutatthione |
| 04/24/2003 | WO2003032965A2 Use of ace inhibitors for reducing type 2 diabetes in high risk patients |
| 04/24/2003 | WO2003032964A2 Gap junctions and endothelial-derived hyperpolarizing factor (edhf) |
| 04/24/2003 | WO2003032963A2 Method of reducing type 2 diabetes in high risk patients |
| 04/24/2003 | WO2003032962A2 Dual action antibiotics |
| 04/24/2003 | WO2003032961A2 Methods for preventing and treating bone loss with steroid compounds |
| 04/24/2003 | WO2003032960A1 Percutaneous absorption preparations |
| 04/24/2003 | WO2003032956A1 Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline |
| 04/24/2003 | WO2003032955A1 Highly compressible ethylcellulose for tableting |
| 04/24/2003 | WO2003032953A1 Granules containing acid-unstable chemical in large amount |
| 04/24/2003 | WO2003032952A1 Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and crohn's disease |
| 04/24/2003 | WO2003032950A1 Pharmaceutical formulation comprising (r) -bicalutamide |
| 04/24/2003 | WO2003032948A2 Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity |
| 04/24/2003 | WO2003032945A1 Binary composition for 'prime-boost' release of active ingredients like vaccines |
| 04/24/2003 | WO2003032944A1 Anti-microbial composition comprising a metal ion chelating agent |
| 04/24/2003 | WO2003032941A2 Cosmetic and/or dermatological active ingredient combination |
| 04/24/2003 | WO2003032931A1 Cosmetic and/or pharmaceutical preparations |
| 04/24/2003 | WO2003032928A2 Therapeutic composition and use |
| 04/24/2003 | WO2003032926A2 Compositions and methods for reversal of drug resistance |
| 04/24/2003 | WO2003032924A2 Novel tibolone formulations |
| 04/24/2003 | WO2003032922A2 Stabilized azithromycin compositions |
| 04/24/2003 | WO2003032921A2 Treatment of neurodegenerative diseases and cancer of the brain |
| 04/24/2003 | WO2003032918A2 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors |
| 04/24/2003 | WO2003032916A2 Organosulfur inhibitors of tyrosine phosphatases |
| 04/24/2003 | WO2003032914A2 Methods for treating substance abuse with cholinesterase inhibitors |
| 04/24/2003 | WO2003032912A2 Treatment of cns disorders using cns target modulators |
| 04/24/2003 | WO2003032910A2 Carbinols for the treatment of neuropathic dysfunction |
| 04/24/2003 | WO2003032909A2 Methods of treating skin with diphosphonate derivatives |
| 04/24/2003 | WO2003032906A2 Delivery of poorly soluble drugs |
| 04/24/2003 | WO2003032905A2 Preparation and use of carbohydrate-based ring structures with antimicrobial and cytostatic activity |
| 04/24/2003 | WO2003032904A2 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi) |
| 04/24/2003 | WO2003032903A2 Trisubstituted triazines compounds with antitubulin activity |
| 04/24/2003 | WO2003032902A2 Tumor targeted photodiagnostic-phototherapeutic agents |
| 04/24/2003 | WO2003032899A2 Methods and materials for targeting and affecting selected cells |
| 04/24/2003 | WO2003032897A2 Azabicyclic compounds for the treatment of fibromyalgia syndrome |
| 04/24/2003 | WO2003032896A2 Dexibuprofen-containing soft gelatin capsules and process for preparing the same |
| 04/24/2003 | WO2003032895A2 Methods and pharmaceutical compositions for stimulating the immune system and/or treating cancer |
| 04/24/2003 | WO2003032894A2 Method of monitoring neuroprotective treatment |
| 04/24/2003 | WO2003032893A2 Assignment |
| 04/24/2003 | WO2003032813A2 Methods for the treatment of carcinoma |
| 04/24/2003 | WO2003032810A2 Treatment and diagnosis of insulin resistant states |
| 04/24/2003 | WO2003032804A2 Reversing or preventing premature vascular senescence |
| 04/24/2003 | WO2003032753A1 Use of cystathionine |
| 04/24/2003 | WO2003032751A1 Alkanoyl l-carnitine metal salts and dietary supplements |
| 04/24/2003 | WO2003032728A2 Methods for preventing or reversing asthma and compositions useful therefor |
| 04/24/2003 | WO2003016282A3 Substituted 1h-dihydropyrazoles, their preparation and use |
| 04/24/2003 | WO2003013449A3 Method of reducing hair growth by applying alpha-difluoromethylornithine |
| 04/24/2003 | WO2003011887A3 Antisense modulation of apolipoprotein b expression |
| 04/24/2003 | WO2003011265A3 5-aminolevulinic acid and esters, in combination with another phtosensitizer, as photosensitizing agents in photochemotherapy, and their uses in treating wounds |
| 04/24/2003 | WO2003009820A3 Methods for promotion of hair growth comprising topical application of prostaglandin analogues |
| 04/24/2003 | WO2003007915A3 Compositions for treatment of head and neck cancers, and methods of making and using the same |
| 04/24/2003 | WO2002102376A8 ORALLY DELIVERABLE PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE COMPOUND HAVING AN AMINOSULFONYL GROUP (cox-2 INHIBITOR), A POLYETHYLENE GLYCOL AND A FREE-RADICAL SCAVENGING ANTIOXIDANT |
| 04/24/2003 | WO2002100437A3 Ophthalmic compositions comprising hyaluronic acid |
| 04/24/2003 | WO2002100389A8 Compressible guaifenesin compositions and method for producing them |
| 04/24/2003 | WO2002099065A3 Compositions and methods for preventing neural tube disorders |
| 04/24/2003 | WO2002098850A3 Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors |
| 04/24/2003 | WO2002094744A3 Compositions comprising d-chiro inositol and sulfonylureas and methods of treatment thereof |
| 04/24/2003 | WO2002089741A3 Compositions and methods for enhancing drug delivery |
| 04/24/2003 | WO2002085292A3 Improved method for treating aberrant fibrotic tisue manifestations with topical calcium channel blocker preparations and improved composition for such treatment and improved method for the manufacture thereof |
| 04/24/2003 | WO2002076509A3 Preparation for the prophylaxis of restenosis |
| 04/24/2003 | WO2002076409A3 Cosmetic and dermatological preparations comprising an isoflavone content |
| 04/24/2003 | WO2002072014A3 Medical devices, compositions and methods for treating vulnerable plaque |
| 04/24/2003 | WO2002070438A3 Compositions for delivering bisphosphonates |
| 04/24/2003 | WO2002069979A3 Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate |
| 04/24/2003 | WO2002068406A3 Substituted amine derivatives and their use for the treatment of angiogenesis |
| 04/24/2003 | WO2002066490A3 Cationic sterol derivatives, ph-sensitive liposomes comprising cationic sterol derivatives and method for loading liposomes with active substances |
| 04/24/2003 | WO2002066025A3 Combination of active ingredients consisting of the racemate of tramadol and of (+)-o-desmethyltramadol |
| 04/24/2003 | WO2002066018A3 Transdermal therapeutic system containing testosterone and method for the production thereof |
| 04/24/2003 | WO2002064809A3 Process for the preparation of one or more statins by fermentation |
| 04/24/2003 | WO2002062299A3 Improved controlled release oral dosage form |
| 04/24/2003 | WO2002060436A8 Use of fredericamycin a and its derivatives in the treatment of pin1-associated states |
| 04/24/2003 | WO2002058690A3 Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors |
| 04/24/2003 | WO2002057259A3 Pyrazole compounds useful as protein kinase inhibitors |
| 04/24/2003 | WO2002056875A3 Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance |
| 04/24/2003 | WO2002053137A3 Pharmaceutical composition for treatment of phimosis using topical corticosteroid |
| 04/24/2003 | WO2002049576A9 Fab i and inhibition of apicomplexan parasites |
| 04/24/2003 | WO2002045710A9 Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| 04/24/2003 | WO2002045707A3 Polynucleotide intercalator interceptors and inhibitors |
| 04/24/2003 | WO2002045431A3 Genetically engineered herpes virus for the treatment of cardiovascular disease |
| 04/24/2003 | WO2002043741A3 Methylenetetrahydrofolate reductase inhibitors and use thereof |
| 04/24/2003 | WO2002024180A3 Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia |
| 04/24/2003 | WO2002017952A3 Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma |
| 04/24/2003 | WO2002017734A3 Materials and methods for the treatment or prevention of obesity |
| 04/24/2003 | WO2001080856A3 Use of anethole-dithiolethione for preventing and treating drug-induced tendon toxicity |